Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$0.55 USD
-0.03 (-4.48%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $0.56 +0.01 (0.99%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GOSS 0.55 -0.03(-4.48%)
Will GOSS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GOSS
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
Other News for GOSS
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib’s Promising Clinical Data and Future Prospects
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street Breakfast: The Week Ahead
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
12 Health Care Stocks Moving In Monday's After-Market Session